Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea
Improvement in Physical Functioning (SF-36 Activity Score) in COPD Patients With Exercise-induced Dyspnoea on Treatment With Spiriva® 18 Microgram (Capsules Containing 18 μg Tiotropium).
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Amberg, Germany
- Boehringer Ingelheim Investigational Site
-
Anklam, Germany
- Boehringer Ingelheim Investigational Site
-
Aschau, Germany
- Boehringer Ingelheim Investigational Site
-
Auerbach, Germany
- Boehringer Ingelheim Investigational Site
-
Augsburg, Germany
- Boehringer Ingelheim Investigational Site
-
Backnang, Germany
- Boehringer Ingelheim Investigational Site
-
Bad Doberan, Germany
- Boehringer Ingelheim Investigational Site
-
Bad Lippspringe, Germany
- Boehringer Ingelheim Investigational Site
-
Bad Oeynhausen, Germany
- Boehringer Ingelheim Investigational Site
-
Bad Soden, Germany
- Boehringer Ingelheim Investigational Site
-
Bad Wörishofen, Germany
- Boehringer Ingelheim Investigational Site
-
Beelitz, Germany
- Boehringer Ingelheim Investigational Site
-
Bensheim, Germany
- Boehringer Ingelheim Investigational Site
-
Bergisch Gladbach, Germany
- Boehringer Ingelheim Investigational Site
-
Berlin, Germany
- Boehringer Ingelheim Investigational Site
-
Biberach, Germany
- Boehringer Ingelheim Investigational Site
-
Bochum, Germany
- Boehringer Ingelheim Investigational Site
-
Bonn, Germany
- Boehringer Ingelheim Investigational Site
-
Braunschweig, Germany
- Boehringer Ingelheim Investigational Site
-
Breisach, Germany
- Boehringer Ingelheim Investigational Site
-
Bremen, Germany
- Boehringer Ingelheim Investigational Site
-
Bremerhaven, Germany
- Boehringer Ingelheim Investigational Site
-
Bruchsal, Germany
- Boehringer Ingelheim Investigational Site
-
Buchholz, Germany
- Boehringer Ingelheim Investigational Site
-
Bünde, Germany
- Boehringer Ingelheim Investigational Site
-
Calw, Germany
- Boehringer Ingelheim Investigational Site
-
Castrop-Rauxel, Germany
- Boehringer Ingelheim Investigational Site
-
Celle, Germany
- Boehringer Ingelheim Investigational Site
-
Chemnitz, Germany
- Boehringer Ingelheim Investigational Site
-
Coburg, Germany
- Boehringer Ingelheim Investigational Site
-
Cottbus, Germany
- Boehringer Ingelheim Investigational Site
-
Darmstadt, Germany
- Boehringer Ingelheim Investigational Site
-
Dillenburg, Germany
- Boehringer Ingelheim Investigational Site
-
Dinslaken, Germany
- Boehringer Ingelheim Investigational Site
-
Dortmund, Germany
- Boehringer Ingelheim Investigational Site
-
Dresden, Germany
- Boehringer Ingelheim Investigational Site
-
Duisburg, Germany
- Boehringer Ingelheim Investigational Site
-
Düren, Germany
- Boehringer Ingelheim Investigational Site
-
Düsseldorf, Germany
- Boehringer Ingelheim Investigational Site
-
Eisenhüttenstadt, Germany
- Boehringer Ingelheim Investigational Site
-
Emden, Germany
- Boehringer Ingelheim Investigational Site
-
Erbach, Germany
- Boehringer Ingelheim Investigational Site
-
Erfurt, Germany
- Boehringer Ingelheim Investigational Site
-
Essen, Germany
- Boehringer Ingelheim Investigational Site
-
Esslingen, Germany
- Boehringer Ingelheim Investigational Site
-
Euskirchen, Germany
- Boehringer Ingelheim Investigational Site
-
Fellbach, Germany
- Boehringer Ingelheim Investigational Site
-
Flensburg, Germany
- Boehringer Ingelheim Investigational Site
-
Forchheim, Germany
- Boehringer Ingelheim Investigational Site
-
Frankfurt, Germany
- Boehringer Ingelheim Investigational Site
-
Freising, Germany
- Boehringer Ingelheim Investigational Site
-
Fürstenfeldbruck, Germany
- Boehringer Ingelheim Investigational Site
-
Fürth, Germany
- Boehringer Ingelheim Investigational Site
-
Gadebusch, Germany
- Boehringer Ingelheim Investigational Site
-
Geilenkirchen, Germany
- Boehringer Ingelheim Investigational Site
-
Gelnhausen, Germany
- Boehringer Ingelheim Investigational Site
-
Gelsenkirchen, Germany
- Boehringer Ingelheim Investigational Site
-
Germering, Germany
- Boehringer Ingelheim Investigational Site
-
Gießen, Germany
- Boehringer Ingelheim Investigational Site
-
Gifhorn, Germany
- Boehringer Ingelheim Investigational Site
-
Gotha, Germany
- Boehringer Ingelheim Investigational Site
-
Greiz, Germany
- Boehringer Ingelheim Investigational Site
-
Gummersbach, Germany
- Boehringer Ingelheim Investigational Site
-
Göppingen, Germany
- Boehringer Ingelheim Investigational Site
-
Gütersloh, Germany
- Boehringer Ingelheim Investigational Site
-
Halberstadt, Germany
- Boehringer Ingelheim Investigational Site
-
Halle, Germany
- Boehringer Ingelheim Investigational Site
-
Hamburg, Germany
- Boehringer Ingelheim Investigational Site
-
Hameln, Germany
- Boehringer Ingelheim Investigational Site
-
Hamm, Germany
- Boehringer Ingelheim Investigational Site
-
Hannover, Germany
- Boehringer Ingelheim Investigational Site
-
Heidelberg, Germany
- Boehringer Ingelheim Investigational Site
-
Heilbronn, Germany
- Boehringer Ingelheim Investigational Site
-
Herne, Germany
- Boehringer Ingelheim Investigational Site
-
Hilden, Germany
- Boehringer Ingelheim Investigational Site
-
Hildesheim, Germany
- Boehringer Ingelheim Investigational Site
-
Hoyerswerda, Germany
- Boehringer Ingelheim Investigational Site
-
Ibbenbüren, Germany
- Boehringer Ingelheim Investigational Site
-
Ingolstadt, Germany
- Boehringer Ingelheim Investigational Site
-
Iserlohn, Germany
- Boehringer Ingelheim Investigational Site
-
Kaiserslautern, Germany
- Boehringer Ingelheim Investigational Site
-
Kamen, Germany
- Boehringer Ingelheim Investigational Site
-
Karlsruhe, Germany
- Boehringer Ingelheim Investigational Site
-
Kaufbeuren, Germany
- Boehringer Ingelheim Investigational Site
-
Kempten, Germany
- Boehringer Ingelheim Investigational Site
-
Kevelaer, Germany
- Boehringer Ingelheim Investigational Site
-
Kiel, Germany
- Boehringer Ingelheim Investigational Site
-
Konstanz, Germany
- Boehringer Ingelheim Investigational Site
-
Krefeld, Germany
- Boehringer Ingelheim Investigational Site
-
Köln, Germany
- Boehringer Ingelheim Investigational Site
-
Landshut, Germany
- Boehringer Ingelheim Investigational Site
-
Langenfeld, Germany
- Boehringer Ingelheim Investigational Site
-
Leipzig, Germany
- Boehringer Ingelheim Investigational Site
-
Limburg, Germany
- Boehringer Ingelheim Investigational Site
-
Lindenberg, Germany
- Boehringer Ingelheim Investigational Site
-
Linz, Germany
- Boehringer Ingelheim Investigational Site
-
Lippstadt, Germany
- Boehringer Ingelheim Investigational Site
-
Ludwigsburg, Germany
- Boehringer Ingelheim Investigational Site
-
Lörrach, Germany
- Boehringer Ingelheim Investigational Site
-
Lüdenscheid, Germany
- Boehringer Ingelheim Investigational Site
-
Lüneburg, Germany
- Boehringer Ingelheim Investigational Site
-
Magdeburg, Germany
- Boehringer Ingelheim Investigational Site
-
Mainz, Germany
- Boehringer Ingelheim Investigational Site
-
Marburg, Germany
- Boehringer Ingelheim Investigational Site
-
Markkleeberg, Germany
- Boehringer Ingelheim Investigational Site
-
Memmingen, Germany
- Boehringer Ingelheim Investigational Site
-
Menden, Germany
- Boehringer Ingelheim Investigational Site
-
Minden, Germany
- Boehringer Ingelheim Investigational Site
-
Moers, Germany
- Boehringer Ingelheim Investigational Site
-
Mönchengladbach, Germany
- Boehringer Ingelheim Investigational Site
-
Mühldorf, Germany
- Boehringer Ingelheim Investigational Site
-
Mülheim, Germany
- Boehringer Ingelheim Investigational Site
-
München, Germany
- Boehringer Ingelheim Investigational Site
-
Neu-Ulm, Germany
- Boehringer Ingelheim Investigational Site
-
Neunkirchen, Germany
- Boehringer Ingelheim Investigational Site
-
Norderstedt, Germany
- Boehringer Ingelheim Investigational Site
-
Nordhausen, Germany
- Boehringer Ingelheim Investigational Site
-
Nürnberg, Germany
- Boehringer Ingelheim Investigational Site
-
Oberursel, Germany
- Boehringer Ingelheim Investigational Site
-
Olpe, Germany
- Boehringer Ingelheim Investigational Site
-
Oschersleben, Germany
- Boehringer Ingelheim Investigational Site
-
Osnabrück, Germany
- Boehringer Ingelheim Investigational Site
-
Papenburg, Germany
- Boehringer Ingelheim Investigational Site
-
Peine, Germany
- Boehringer Ingelheim Investigational Site
-
Plauen, Germany
- Boehringer Ingelheim Investigational Site
-
Potsdam, Germany
- Boehringer Ingelheim Investigational Site
-
Pulheim, Germany
- Boehringer Ingelheim Investigational Site
-
Rastatt, Germany
- Boehringer Ingelheim Investigational Site
-
Rathenow, Germany
- Boehringer Ingelheim Investigational Site
-
Regensburg, Germany
- Boehringer Ingelheim Investigational Site
-
Remscheid, Germany
- Boehringer Ingelheim Investigational Site
-
Rendsburg, Germany
- Boehringer Ingelheim Investigational Site
-
Rostock, Germany
- Boehringer Ingelheim Investigational Site
-
Rüdersdorf, Germany
- Boehringer Ingelheim Investigational Site
-
Rüsselsheim, Germany
- Boehringer Ingelheim Investigational Site
-
Saarbrücken, Germany
- Boehringer Ingelheim Investigational Site
-
Saarlouis, Germany
- Boehringer Ingelheim Investigational Site
-
Salzgitter, Germany
- Boehringer Ingelheim Investigational Site
-
Schenefeld, Germany
- Boehringer Ingelheim Investigational Site
-
Schleswig, Germany
- Boehringer Ingelheim Investigational Site
-
Schmölln, Germany
- Boehringer Ingelheim Investigational Site
-
Schwalmstadt, Germany
- Boehringer Ingelheim Investigational Site
-
Schwalmtal, Germany
- Boehringer Ingelheim Investigational Site
-
Schwerin, Germany
- Boehringer Ingelheim Investigational Site
-
Sebnitz, Germany
- Boehringer Ingelheim Investigational Site
-
Seevetal, Germany
- Boehringer Ingelheim Investigational Site
-
Siegen, Germany
- Boehringer Ingelheim Investigational Site
-
Singen, Germany
- Boehringer Ingelheim Investigational Site
-
Sinsheim, Germany
- Boehringer Ingelheim Investigational Site
-
Solingen, Germany
- Boehringer Ingelheim Investigational Site
-
Sonneberg, Germany
- Boehringer Ingelheim Investigational Site
-
Spremberg, Germany
- Boehringer Ingelheim Investigational Site
-
Stade, Germany
- Boehringer Ingelheim Investigational Site
-
Starnberg, Germany
- Boehringer Ingelheim Investigational Site
-
Steinbach, Germany
- Boehringer Ingelheim Investigational Site
-
Straelen, Germany
- Boehringer Ingelheim Investigational Site
-
Strausberg, Germany
- Boehringer Ingelheim Investigational Site
-
Stuttgart, Germany
- Boehringer Ingelheim Investigational Site
-
Teltow, Germany
- Boehringer Ingelheim Investigational Site
-
Teterow, Germany
- Boehringer Ingelheim Investigational Site
-
Troisdorf, Germany
- Boehringer Ingelheim Investigational Site
-
Unna, Germany
- Boehringer Ingelheim Investigational Site
-
Uttenreuth, Germany
- Boehringer Ingelheim Investigational Site
-
Verden, Germany
- Boehringer Ingelheim Investigational Site
-
Waiblingen, Germany
- Boehringer Ingelheim Investigational Site
-
Waren, Germany
- Boehringer Ingelheim Investigational Site
-
Warendorf, Germany
- Boehringer Ingelheim Investigational Site
-
Weiden, Germany
- Boehringer Ingelheim Investigational Site
-
Weißenhorn, Germany
- Boehringer Ingelheim Investigational Site
-
Wetzlar, Germany
- Boehringer Ingelheim Investigational Site
-
Wiesloch, Germany
- Boehringer Ingelheim Investigational Site
-
Wilhelmshaven, Germany
- Boehringer Ingelheim Investigational Site
-
Witten, Germany
- Boehringer Ingelheim Investigational Site
-
Worms, Germany
- Boehringer Ingelheim Investigational Site
-
Wuppertal, Germany
- Boehringer Ingelheim Investigational Site
-
Zella-Mehlis, Germany
- Boehringer Ingelheim Investigational Site
-
Zossen, Germany
- Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Men or women with COPD and a thoracic gas volume (TGV) of < 140% at rest, MRC value of 2 or more.
Exclusion Criteria:
- Patients cannot be recruited if any of the general or specific contraindications listed in the Patient information leaflet or the Summary of Product Characteristics applies.
- Tiotropium bromide inhalation powder is contraindicated in patients with a hypersensitivity to tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium or to the excipient lactose monohydrate which contains milk protein.
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary endpoint was the proportion of patients with an improvement by ≥10 points in the standardised PF-10 score after 6 weeks of treatment with Spiriva® 18 Microgram
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The secondary endpoint was the change in the standardised PF-10 score within 6 weeks of treatment with Spiriva® 18 Microgram
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 205.402
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.